A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy

Pharmaceuticals · 3 authors, 4 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

The authors conclude that GLP-1 agonists show promise but lack sufficient trial evidence, and call for pharmacogenetic and polypharmacy research.

Full summary

253 CHARS

The authors note that GLP-1 agonists do not yet have enough trials to argue they are effective in treating DPN but could be a promising intervention. The authors highlight the need for pharmacogenetic trials and research on polypharmacy treatment plans.

STUDY TYPE

narrative_review

SPECIALTY

neurology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10304825

A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy

Pharmaceuticals

READ THE FULL PAPER

ABSTRACT

Abstract Diabetic peripheral neuropathy is a common complication of longstanding diabetes mellitus. These neuropathies can present in various forms, and with the increasing prevalence of diabetes mellitus, a subsequent increase in peripheral neuropathy cases has been noted. Peripheral neuropathy has a significant societal and economic burden, with patients requiring concomitant medication and often experiencing a decline in their quality of life. There is currently a wide variety of pharmacological interventions, including serotonin norepinephrine reuptake inhibitors, gapentanoids, sodium channel blockers, and tricyclic antidepressants. These medications will be discussed, as well as their respective efficacies. Recent advances in the treatment of diabetes mellitus with incretin system-modulating drugs, specifically glucagon-like peptide-1 agonists, have been promising, and their potential implication in the treatment of peripheral diabetic neuropathy is discussed in this review. Keywords: diabetic peripheral neuropathy, diabetes, neuropathic pain, GLP-1

CITATION EXPORT

Osman Syed, Predrag Jancic, Nebojsa Nick Knezevic. A Review of Recent Pharmacological Advances in the Management of Diabetes-Associated Peripheral Neuropathy. Pharmaceuticals. (2023). https://doi.org/10.3390/ph16060801

AUTHORS

3 · 4 CENTRES

Osman Syed, Predrag Jancic, Nebojsa Nick Knezevic

1Advocate Illinois Masonic Medical Center, Department of Anesthesiology, Chicago, IL 60657, USA; [email protected] (O.S.); [email protected] (P.J.)
2Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
3Department of Anesthesiology, University of Illinois, Chicago, IL 60612, USA
4Department of Surgery, University of Illinois, Chicago, IL 60612, USA